#United States #CFO #TransMedics #Andover #Fernando Araujo

Fernando Araujo Appointed Chief Financial Officer of TransMedics

TransMedics Group, Inc. (Nasdaq: TMDX), a leader in the innovative field of portable warm perfusion for donor organs, has made a significant executive appointment by bringing on board Fernando Araujo as their new Chief Financial Officer (CFO). Effective September 21, 2026, Araujo steps into the role amid aspirations to bolster the company's global growth trajectory. He succeeds Gerardo Hernandez, who is transitioning to a position focused on strategic advisory in commercial expansion within Latin America.

In a landscape where healthcare technology is evolving rapidly, TransMedics is at a critical juncture. Araujo, armed with over two decades of experience in finance leadership within major corporations like GE HealthCare, General Electric, and 3M, is set to lend his expertise to the organization. His previous role was as CFO of GE HealthCare’s Advanced Imaging Solutions segment, where he adeptly managed a $16 billion portfolio while playing a pivotal part in operational and financial transformations at GE. His extensive background across various sectors, including healthcare and energy, positions him well for the challenges and opportunities that lie ahead for TransMedics.

A New Era for TransMedics
As TransMedics aims to expand its operations and product offerings, Araujo's appointment is not merely a change in leadership; it is a strategic move designed to align the company’s financial operations with its ambitious growth plans. Waleed Hassanein, M.D., President and Chief Executive Officer, spoke highly of Araujo's fit for the company’s vision, stating, "Fernando joins TransMedics at a growth inflection point... we are confident he will help us capitalize on the significant growth opportunities ahead."

Hassanein emphasizes that Araujo's proven track record of scaling financial operations in complex environments will complement the company's strategy of rapid growth across various dimensions, including expanding product lines and increasing operating leverage. This strategic appointment comes at a time when the company is also looking toward international expansion, particularly in Europe.

Commitment to Shareholders
In conjunction with the leadership transition, TransMedics reaffirmed its revenue guidance for 2026, forecasting between $737 million and $757 million, indicating a robust year-over-year growth of 22% to 25%. Notably, this financial outlook does not take into account the expected contributions from the company’s recent investment in PAD Aviation Service GmbH. The projected figures and focus on disciplined execution aim to underline the organization’s commitment to creating sustainable value for its shareholders.

As the healthcare technology ecosystem continues to expand, Araujo's arrival signifies a pivotal shift within TransMedics, aiming not just for growth but meaningful impact in transplant therapies. He himself expressed enthusiasm about joining the company, emphasizing the potential for lasting value creation and a strong collaboration with the leadership team to achieve the company's mission: enhancing the quality of life for transplant patients.

Looking Ahead
In the coming weeks, TransMedics will be participating in various investor conferences, continuing to cultivate relationships within the investment community. Notably, management will partake in events at the Morgan Stanley 24th Annual Global Healthcare Conference and the Baird 2026 Global Healthcare Conference, showcasing their strategic plans and updates on organizational progress. Both engagements provide platforms not only to discuss financials but also to connect with investors on a vision for innovation in organ transplant technologies.

About TransMedics Inc.
Founded with a clear mission to enhance organ transplantation methods, TransMedics has pioneered technologies for the portable extracorporeal perfusion and assessment of organs. Headquartered in Andover, Massachusetts, the company addresses the critical needs surrounding organ viability and quality before transplant procedures. As the world faces increased demand for transplants, TransMedics represents hope for improved outcomes for patients suffering from end-stage organ failure.

In summary, the appointment of Fernando Araujo as CFO offers a promising outlook for TransMedics as it embarks on an ambitious growth trajectory while remaining committed to its mission of improving transplant therapies.